CI-1040 (CAS 212631-79-3), also known as PF-01269542, is a selective inhibitor of MEK1 and MEK2 kinases that are involved in the MAPK/ERK signaling pathway. This pathway plays a central role in regulating cell growth, proliferation, and survival. Because of its ability to block MEK activity, ci 1040 has become an important research compound in studies focused on cancer biology and targeted therapy development.
Scientists frequently investigate the activity of ci 1040 mek inhibitor in models of tumor progression and signaling pathway regulation. The compound is characterized by a defined molecular formula and stable chemical properties suitable for laboratory applications. Researchers working in pharmaceutical discovery and academic laboratories often buy 212631-79-3 as a reference molecule for evaluating MEK inhibition and validating experimental systems.
Application of CI-1040
CI-1040 is widely used in biomedical research exploring signaling pathways associated with cancer and cell proliferation. By inhibiting MEK1/2 activity, the compound helps researchers investigate how MAPK signaling contributes to disease progression and therapeutic response.
- Research on MAPK/ERK signaling pathways
- Development of targeted cancer therapies
- Screening of novel kinase inhibitors
- Validation of MEK inhibition in experimental models
Because of its well-characterized mechanism, ci 1040 is often used as a reference inhibitor in kinase-related studies.
In Vitro
In vitro studies demonstrate that CI-1040 effectively inhibits MEK1 and MEK2 kinase activity, preventing phosphorylation of ERK proteins in the MAPK signaling cascade. This inhibition suppresses downstream signaling events responsible for cell proliferation and survival. Researchers frequently apply CI-1040 in cultured cancer cell lines to evaluate pathway inhibition and investigate resistance mechanisms associated with targeted therapies.
In Vivo
In vivo experiments have shown that MEK inhibition by CI-1040 can reduce tumor growth in preclinical models. These studies help researchers understand how blocking the MAPK pathway influences tumor progression, cellular signaling networks, and treatment response. As a result, PF-01269542 has played a role in advancing the development of next-generation MEK inhibitors.
Biochemical and Physiological Actions
The biochemical activity of CI-1040 is based on selective inhibition of MEK1/2 kinases within the MAPK signaling pathway. By preventing activation of ERK proteins, the compound interrupts key signaling events that regulate cell cycle progression and proliferation. This mechanism makes CI-1040 a valuable research tool for studying oncogenic signaling networks and kinase-driven cellular processes.
Features and Benefits of CI-1040
CI-1040 is widely used in laboratory research due to its selective mechanism and well-documented biological activity.
- Selective inhibitor of MEK1 and MEK2 kinases
- Important tool for studying MAPK/ERK signaling pathways
- Useful reference compound in kinase inhibitor screening
- Applicable in both in vitro and in vivo experimental systems
Reliable access to bioactive compounds is essential for modern drug discovery and biomedical research. Research teams in pharmaceutical, biotechnology, and academic sectors rely on validated molecules to support screening programs and mechanistic investigations, enabling faster progress in understanding disease pathways and developing targeted therapies.
